Literature DB >> 19645066

Atypical antipsychotic use and risk of fracture in persons with Parkinsonism.

David D Dore1, Amal N Trivedi, Vincent Mor, Joseph H Friedman, Kate L Lapane.   

Abstract

Our objective was to estimate the effect of atypical antipsychotics (AAs) on the rate of fractures in a parkinsonism population. We conducted an age- and state-matched nested case-control study in five states (CA, FL, NY, OH, IL) using the Medicaid analytic extract from 2001 to 2002. Eligible participants had a diagnosis of parkinsonism, excluding persons with secondary parkinsonism, bone cancer, bone infections, schizophrenia, schizoaffective disorder, and those who used conventional antipsychotics. The primary outcome was the occurrence of a fracture of the femur, ankle, fibula, tibia, humerus, radius, or ulna (N = 851). Risk-set sampling defined controls (N = 4220). We used conditional-logistic regression to derive adjusted odds ratios (AOR) and 95% confidence intervals of the association between fracture and use of quetiapine, risperidone, or olanzapine in the 60 days before the index date compared to nonuse. After adjustment for confounding, use of quetiapine (AOR 2.4; 95% CI 1.5-3.8), risperidone (AOR 1.2; 95% CI 0.9-1.7), or olanzapine (AOR 1.7; 95% CI 1.2-2.4) was associated with a higher rate of fracture. Use of an AA was associated with a higher rate of fracture in persons with parkinsonism. Prescribers must be cautious when using these agents in elderly persons with parkinsonism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19645066     DOI: 10.1002/mds.22679

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  9 in total

Review 1.  Use of antipsychotics increases the risk of fracture: a systematic review and meta-analysis.

Authors:  S-H Lee; W-T Hsu; C-C Lai; A Esmaily-Fard; Y-W Tsai; C-C Chiu; J Wang; S-S Chang; C C Lee
Journal:  Osteoporos Int       Date:  2017-01-12       Impact factor: 4.507

Review 2.  Weight Loss in Patients with Dementia: Considering the Potential Impact of Pharmacotherapy.

Authors:  Bart A A Franx; Ilse A C Arnoldussen; Amanda J Kiliaan; Deborah R Gustafson
Journal:  Drugs Aging       Date:  2017-06       Impact factor: 3.923

3.  Propranolol Attenuates Risperidone-Induced Trabecular Bone Loss in Female Mice.

Authors:  Katherine J Motyl; Victoria E DeMambro; Deborah Barlow; David Olshan; Kenichi Nagano; Roland Baron; Clifford J Rosen; Karen L Houseknecht
Journal:  Endocrinology       Date:  2015-04-08       Impact factor: 4.736

4.  Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis.

Authors:  Daniel Weintraub; Peijun Chen; Rosalinda V Ignacio; Eugenia Mamikonyan; Helen C Kales
Journal:  Arch Neurol       Date:  2011-07

5.  Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain.

Authors:  Katherine J Motyl; Ingrid Dick-de-Paula; Ann E Maloney; Sutada Lotinun; Sheila Bornstein; Francisco J A de Paula; Roland Baron; Karen L Houseknecht; Clifford J Rosen
Journal:  Bone       Date:  2011-08-11       Impact factor: 4.398

6.  A novel role for dopamine signaling in the pathogenesis of bone loss from the atypical antipsychotic drug risperidone in female mice.

Authors:  Katherine J Motyl; Megan Beauchemin; Deborah Barlow; Phuong T Le; Kenichi Nagano; Annika Treyball; Anisha Contractor; Roland Baron; Clifford J Rosen; Karen L Houseknecht
Journal:  Bone       Date:  2017-07-06       Impact factor: 4.398

7.  Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease.

Authors:  Daniel Weintraub; Claire Chiang; Hyungjin Myra Kim; Jayne Wilkinson; Connie Marras; Barbara Stanislawski; Eugenia Mamikonyan; Helen C Kales
Journal:  JAMA Neurol       Date:  2016-05-01       Impact factor: 18.302

8.  Atypical antipsychotic use in patients with dementia: managing safety concerns.

Authors:  Martin Steinberg; Constantine G Lyketsos
Journal:  Am J Psychiatry       Date:  2012-09       Impact factor: 18.112

9.  Identifying rates and risk factors for medication errors during hospitalization in the Australian Parkinson's disease population: A 3-year, multi-center study.

Authors:  Michael Bakker; Michaela E Johnson; Lauren Corre; Deanna N Mill; Xingzhuo Li; Richard J Woodman; Jacinta L Johnson
Journal:  PLoS One       Date:  2022-05-04       Impact factor: 3.752

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.